(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetic acid methyl ester | 946131-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetic acid methyl ester
• 英文别名: (5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)acetic acid methyl ester；Methyl 2-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)acetate；methyl 2-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)acetate
• CAS: 946131-96-0
• 化学式: C₁₄H₁₅NO₂
• 分子量: 229.279
• InChiKey: LXACCDJGRWGNJC-UHFFFAOYSA-N

物化性质

• 熔点：
  103-105 °C(Solv: ethanol (64-17-5))
• 沸点：
  397.9±27.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetic acid methyl ester 在 palladium on activated charcoal 、 氢气 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 生成 2-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-3-(1H-indol-3-yl)succinic acid dimethyl ester
  参考文献：
  名称：

  COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

  摘要：

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。

  公开号：

  US20150328208A1
• 作为产物：
  描述：

  (5,6-dihydro-4H-pyrrolo<3,2,1-ij>quinolin-1-yl)acetic acid 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以67%的产率得到(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)acetic acid methyl ester
  参考文献：
  名称：

  Design, synthesis and melatoninergic activity of new unsubstituted and β,β′-difunctionalised 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides

  摘要：

  A series of new 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides, with and without alkyl and cycloalkyl moieties in the P-position of the alkanamido side chain, have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. An increase of the spacer's length in the side chain by a methylene unit (from 17d to 21d) leads to a six-fold decrease in antagonistic activity. On the other hand, the introduction of two methyl groups in the beta-position of the side chain of 17a induces agonist potency (compound 24), implying thus that the two beta-methyl groups are not only tolerated by the receptor, but constitute functional probes in its dynamic agonist-antagonist conformational equilibrium. The presence of more bulky beta-substituents, regardless of the size of the R group, compounds 24a,b, seems to lead to antagonism and to a noteworthy MT2 subtype selectivity. Last, the new N1-C7 annulated derivatives presented herein are substantially more potent than their respective N1-C2 annulated counterparts, previously reported. (c) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.01.005

文献信息

• Substituted Heterocyclic Compounds
  申请人：Ali Syed M.

  公开号：US20110160237A1

  公开（公告）日：2011-06-30

  The present invention relates to substituted heterocyclic compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted heterocyclic compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及替代杂环化合物及其合成方法。本发明还涉及含有替代杂环化合物的药物组合物以及通过向需要的受试者投与这些化合物和药物组合物来治疗细胞增殖性疾病，如癌症的方法。
• [EN] COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER<br/>[FR] COMPOSITIONS COMBINATOIRES ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER
  申请人：ARQULE INC

  公开号：WO2010093789A2

  公开（公告）日：2010-08-19

  The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

  本发明提供了一种治疗细胞增殖性疾病（如癌症）的方法，通过向需要治疗的受试者施用一种吡咯喹啉基-吡咯烷-2,5-二酮化合物或吡咯喹啉基-吡咯啉-2,5-二酮化合物的治疗有效量，与治疗有效量的第二种抗增殖剂联合使用。
• Compositions and methods for treatment of cancer
  申请人：Li J. Chiang

  公开号：US20060223760A1

  公开（公告）日：2006-10-05

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物，以及这些化合物的制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物的药物组合物。本发明提供了通过向需要治疗细胞增殖性疾病，如癌症的患者投与本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯啉-2,5-二酮化合物的治疗有效量的方法。
• Compositions and Methods for Treatment of Cancer
  申请人：Li Chiang J.

  公开号：US20100221251A1

  公开（公告）日：2010-09-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物及其制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的制药组合物。本发明提供了通过向需要治疗细胞增殖性疾病，例如癌症的患者施用本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物的治疗有效量的方法。
• Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer
  申请人：ArQule, Inc.

  公开号：EP2289892A1

  公开（公告）日：2011-03-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物，以及这些化合物的制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的药物组合物。本发明提供了治疗细胞增殖性疾病（如癌症）的方法，即向有需要的受试者施用治疗有效量的本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物。